We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.25B
AUM Growth
+$165M
Cap. Flow
+$181M
Cap. Flow %
14.45%
Top 10 Hldgs %
67.15%
Holding
42
New
8
Increased
10
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$63.8M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$33.1M
3
TYRA icon
Tyra Biosciences
TYRA
+$23.9M
4
VRDN icon
Viridian Therapeutics
VRDN
+$22.1M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.8M

Top Sells

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$57.4M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.68M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.37M
4
RGNX icon
Regenxbio
RGNX
+$4.18M
5
BLU
BELLUS Health Inc.
BLU
+$3.27M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$201M 16.12%
8,434,232
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$187M 14.97%
5,827,415
– –
MIRM icon
3
Mirum Pharmaceuticals
MIRM
$6.08B
$71.1M 5.69%
3,566,912
– –
IOVA icon
4
Iovance Biotherapeutics
IOVA
$3.74B
$65.9M 5.28%
2,674,299
+536,300
+25% +$12.6M
IMGO
5
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$59.5M 4.76%
+2,971,274
New +$63.8M
PCVX icon
6
Vaxcyte
PCVX
$9.1B
$58.6M 4.69%
2,309,554
– –
TRIL
7
DELISTED
Trillium Therapeutics Inc.
TRIL
$55M 4.4%
3,123,107
– –
GRTS
8
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$50.4M 4.03%
4,667,242
+3,636,364
+353% +$33.1M
PASG icon
9
Passage Bio
PASG
$13.9M
$49.9M 3.99%
250,461
– –
KRYS icon
10
Krystal Biotech
KRYS
$10.6B
$40.3M 3.22%
771,250
-16,626
-2% -$984K
TARS icon
11
Tarsus Pharmaceuticals
TARS
$3.16B
$30.5M 2.44%
1,417,157
– –
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$29.9M 2.39%
1,838,402
-706,098
-28% -$7.68M
STRO icon
13
Sutro Biopharma
STRO
$353M
$27.7M 2.22%
146,866
+46,724
+47% +$8.88M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.71B
$24.8M 1.98%
+1,505,200
New +$22.1M
ANAB icon
15
AnaptysBio
ANAB
$1.7B
$24.4M 1.95%
899,700
– –
AUTL
16
Autolus Therapeutics
AUTL
$628M
$23.1M 1.85%
3,530,657
+1,246,691
+55% +$7.88M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.8B
$22.7M 1.82%
1,188,135
– –
TYRA icon
18
Tyra Biosciences
TYRA
$1.56B
$22M 1.76%
+1,250,000
New +$23.9M
KDNY
19
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$21.3M 1.71%
1,671,918
+571,918
+52% +$7.53M
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$18.9M 1.51%
1,771,844
-799,606
-31% -$7.37M
BCYC
21
Bicycle Therapeutics
BCYC
$303M
$18.4M 1.47%
+442,880
New +$15.5M
CRNX icon
22
Crinetics Pharmaceuticals
CRNX
$9B
$17.9M 1.43%
+851,306
New +$17.8M
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$17.6M 1.41%
804,667
+601,864
+297% +$12M
FLACU
24
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15.1M 1.2%
1,501,000
– –
REPL icon
25
Replimune Group
REPL
$1.47B
$14.6M 1.17%
+491,998
New +$16M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q3 2021 Portfolio in Review

As of Q3 2021, Frazier Management held 42 positions worth $1.25B, up 15% from $1.08B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Management deployed $181M of net new capital in Q3 2021, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Imago BioSciences, Inc. Common stock: 2,971,274 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $7.68M trimmed.

  • Frazier Management's largest Q3 2021 buy was Imago BioSciences, Inc. Common stock: 2,971,274 shares worth $59.5M.
  • Frazier Management added most to Gritstone bio, Inc. Common Stock in Q3 2021, an estimated $33.1M increase.
  • Frazier Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $7.68M.
  • Frazier Management fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $57.4M.
  • Frazier Management's ten largest holdings make up 67% of its $1.25B portfolio in Q3 2021.
  • Frazier Management opened 8 new positions and closed 1 in Q3 2021.
  • Frazier Management's portfolio value rose 15% quarter-over-quarter to $1.25B.

Based on Frazier Management's 13F filing for Q3 2021, filed 12 Nov 2021.